Enhanced Procoagulant Activity of Select Hemophilia B Causing Factor IX Variants with Emicizumab.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
accepted:
25
06
2024
received:
21
07
2023
revised:
20
06
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
10
7
2024
Statut:
aheadofprint
Résumé
Emicizumab improves the procoagulant activity of select loss-of-function FIX variants with likely dysfunctional assembly of the intrinsic Xase complex that cause hemophilia B. FVIII-mimetics may represent an alternative non-factor therapy for select hemophilia B patients.
Identifiants
pubmed: 38985830
pii: 516932
doi: 10.1182/blood.2023021944
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 American Society of Hematology.